GenScript has signed biology research collaboration with Roche R&D Center (RRDCC), a subsidiary of Roche since early 2009.
Under the agreement, GenScript is set to provide assay development services for potential drug targets in line with Roche’s drug development portfolio.
Li Chen, chief scientific officer of Roche R&D Center, said: “After the success of medicinal chemistry outsourcing, biology CRO is becoming a new trend in drug discovery. We expect a fruitful collaboration with GenScript in assay development.
“We appreciate the confidence that RRDCC has shown in GenScript, and believe that the collaboration will mutually benefit us.
GenScript is a contract research organization (CRO) focused in biological research and drug discovery services. Its service portfolio includes bio-reagent services, assay development & screening, lead optimisation, and antibody drug development.